Back to Resource Center

Estimating the costs and perceived benefits of oral preexposure prophylaxis (PrEP) delivery in ten counties of Kenya: A costing and a contingent valuation study

Kenya included oral PrEP in the national guidelines as part of combination HIV prevention, and subsequently began providing PrEP to individuals who are at elevated risk of HIV infection in 2017. However, as scale-up continued, there was a recognized gap in knowledge on the cost of delivering oral PrEP. This gap limited the ability of the Government of Kenya to budget for its PrEP scale-up and to evaluate PrEP relative to other HIV prevention strategies. The following study calculated the actual costs of oral PrEP scale-up as it was being delivered in ten counties in Kenya. This costing also allowed for a comparison of various models of service delivery in different geographic regions from the perspective of service providers in Kenya. In addition, the analysis was also conducted to understand factors that indicate why some individuals place a greater value on PrEP than others, using a contingent valuation technique.

February 2024

Click for full info +

Full Info:


Resource Type:

Database
Journal Article
Journal Article
Resource

Citation:

Kenya included oral PrEP in the national guidelines as part of combination HIV prevention, and subsequently began providing PrEP to individuals who are at elevated risk of HIV infection in 2017. However, as scale-up continued, there was a recognized gap in knowledge on the cost of delivering oral PrEP. This gap limited the ability of the Government of Kenya to budget for its PrEP scale-up and to evaluate PrEP relative to other HIV prevention strategies. The following study calculated the actual costs of oral PrEP scale-up as it was being delivered in ten counties in Kenya. This costing also allowed for a comparison of various models of service delivery in different geographic regions from the perspective of service providers in Kenya. In addition, the analysis was also conducted to understand factors that indicate why some individuals place a greater value on PrEP than others, using a contingent valuation technique.

View Journal Article

Authors: Forsythe, S., Kioko, U., Mahiane, G., Glaubius, R., Musau, A., Gichangi, A., Reed, J. and Were, D.

Health Risks(s):

  • HIV

Product type(s):

  • ARVs
  • HIVinhibitor

Topic(s):

  • Product Introduction

Region(s)

  • Africa

Back to Resource Center